Citius Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended June 30, 2023. The financial statements are unaudited. Citius is a development-stage biopharmaceutical company focused on oncology, anti-infectives, prescription products, and stem-cell therapies; it reported no revenue in either the quarter or nine-month period.
Financial performance and position
| Metric | Three months ended June 30, 2023 | Nine months ended June 30, 2023 | Comparable 2022 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development | $3.76 million | $11.94 million | $4.89 million; $13.80 million |
| General and administrative | $3.73 million | $11.13 million | $3.02 million; $9.04 million |
| Total operating expenses | $8.67 million | $26.61 million | $8.92 million; $25.77 million |
| Net loss | $8.48 million | $22.60 million | $8.86 million; $25.65 million |
| Loss per share, basic and diluted | $0.06 | $0.15 | $0.06; $0.18 |
- Cash and liquidity: Cash and cash equivalents were $33.28 million at June 30, 2023, down from $41.71 million at September 30, 2022. Working capital was approximately $35.3 million. Management estimated cash resources would fund operations through August 2024.
- Cash flow: Operating cash use was $22.26 million for the nine months, versus $22.03 million in 2022. A May 2023 registered direct offering generated $13.80 million in net proceeds; total cash declined by $8.43 million over the period.
- Balance sheet and debt: Total assets were $110.40 million and total liabilities were $12.10 million. The balance sheet reports no conventional borrowing debt; liabilities included accounts payable, accruals, deferred taxes, and operating lease obligations.
- Margins: No revenue was recorded, so revenue-based margins are not meaningful.
Material changes versus the prior period
- Quarterly net loss narrowed by $0.38 million, mainly as R&D costs fell $1.12 million, partly offset by a $0.71 million increase in G&A, including Lymphir pre-launch and market-research spending.
- Nine-month net loss narrowed by $3.05 million. The comparison benefited from $3.59 million in proceeds-related gain on the sale of New Jersey tax losses and higher interest income; operating expenses increased by $0.84 million and income tax expense was $0.43 million.
- Nine-month R&D decreased overall, reflecting lower Lymphir and NoveCite costs, while Halo-Lido trial spending increased. G&A and stock-based compensation also increased year over year.
- The May offering issued 12.5 million common shares and warrants to buy 12.5 million additional shares, plus 875,000 placement-agent warrants. Common shares outstanding were 158,857,798 at June 30, 2023.
Outlook, risks, and unusual items
- Lymphir: On July 29, 2023, after quarter-end, the FDA issued a Complete Response Letter for the biologics license application. The FDA required enhanced product testing and additional controls, while raising no concerns about the safety and efficacy clinical data package. Citius said remediation was not expected to affect its 12-month cash runway. Approval and launch timing remain uncertain.
- Development plans: Management expected R&D spending to stabilize in fiscal 2023 while focusing on Lymphir commercialization and completion of the Phase 3 Mino-Lok and Phase 2b Halo-Lido trials. Halo-Lido enrollment was completed; management planned an end-of-Phase-2 meeting with the FDA.
- Funding risk: The company has generated no operating revenue and expects to need additional capital beyond August 2024. It cautioned that financing, strategic partnerships, regulatory approvals, and commercial sales are not assured; inability to secure funding or generate sales could materially harm the business.
- Potential dilution and commitments: At June 30, 50.9 million warrants were outstanding, in addition to 13.4 million company stock options and 11.7 million shares available for future grants. License agreements also include potential milestones, royalties, and other payments, including substantial contingent Lymphir and NoveCite obligations.
- Other items: The nine-month results included a $3.59 million gain from selling New Jersey net operating losses. In August 2023, certain 2018 warrants held by the CEO, an executive vice president, and placement-agent representatives were extended by one year.
Key investor verification points
- Confirm the FDA’s remediation requirements, expected resubmission or approval schedule for Lymphir, and any associated costs or runway effects.
- Track actual cash burn and financing needs against management’s August 2024 runway estimate, including whether projected spending or trial plans change.
- Verify Mino-Lok trial progress and regulatory pathway, and follow Halo-Lido’s next development steps after the Phase 2b results.
- Assess potential dilution from outstanding warrants, options, future grants, and any additional capital raises.
- Review contingent license milestones, royalties, and commercialization obligations, particularly those tied to Lymphir and NoveCite.